Kiyotaka Nakamagoe

Genetic and Functional Analyses of Patients with Marked Hypo-High-Density Lipoprotein Cholesterolemia.

Journal: Journal of atherosclerosis and thrombosis

Published: March 27, 2024

Correction to: Saccadic oscillations as a biomarker of clinical symptoms in amyotrophic lateral sclerosis.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: June 06, 2023

Characteristics of hypersomnia due to inflammatory demyelinating diseases of the central nervous system.

Journal: BMJ neurology open

Published: February 28, 2023

Waldenström macroglobulinemia complicated by peripheral neuropathy due to neural infiltration

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: February 12, 2023

Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: February 05, 2023

Glutamine/arginine site-unedited GluA2 mRNA in cerebrospinal fluid as a biomarker for amyotrophic lateral sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: January 25, 2023

Saccadic oscillations as a biomarker of clinical symptoms in amyotrophic lateral sclerosis.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: January 01, 2023

Correction to: Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: August 16, 2021

Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: May 12, 2021

Genetic and Functional Analyses of Patients with Marked Hypo-High-Density Lipoprotein Cholesterolemia.

Genetic and Functional Analyses of Patients with Marked Hypo-High-Density Lipoprotein Cholesterolemia.

Correction to: Saccadic oscillations as a biomarker of clinical symptoms in amyotrophic lateral sclerosis.

Correction to: Saccadic oscillations as a biomarker of clinical symptoms in amyotrophic lateral sclerosis.

Characteristics of hypersomnia due to inflammatory demyelinating diseases of the central nervous system.

Characteristics of hypersomnia due to inflammatory demyelinating diseases of the central nervous system.

Waldenström macroglobulinemia complicated by peripheral neuropathy due to neural infiltration

Waldenström macroglobulinemia complicated by peripheral neuropathy due to neural infiltration

Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration.

Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration.

Glutamine/arginine site-unedited GluA2 mRNA in cerebrospinal fluid as a biomarker for amyotrophic lateral sclerosis.

Glutamine/arginine site-unedited GluA2 mRNA in cerebrospinal fluid as a biomarker for amyotrophic lateral sclerosis.

Saccadic oscillations as a biomarker of clinical symptoms in amyotrophic lateral sclerosis.

Saccadic oscillations as a biomarker of clinical symptoms in amyotrophic lateral sclerosis.

Correction to: Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day.

Correction to: Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day.

Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day.

Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day.

Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis.

Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis.

Fisher syndrome as an immune-related adverse event after using pembrolizumab but not nivolumab.

Fisher syndrome as an immune-related adverse event after using pembrolizumab but not nivolumab.

Splice-site mutations in KIF5A in the Japanese case series of amyotrophic lateral sclerosis.

Splice-site mutations in KIF5A in the Japanese case series of amyotrophic lateral sclerosis.